The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients survival

In conclusion, in the clinic, rs34180180 SNP genotyping could improve the prognostic value of the MGMT promoter methylation assay in patients with aggressive glioma treated with TMZ.

Source: Carcinogenesis - February 8, 2016 Category: Cancer & Oncology Authors: Fogli, A., Chautard, E., Vaurs-Barriere, C., Pereira, B., Müller-Barthelemy, M., Court, F., Biau, J., Pinto, A. A., Kemeny, J.-L., Khalil, T., Karayan-Tapon, L., Verrelle, P., Costa, B. M., Arnaud, P. Tags: Original Manuscript Source Type: research